Navigation Links
Effect on breast tumors of DNA alternations in 3 genes described

Cancer epidemiologists at the University at Buffalo have identified specific genes that are most likely to become cancer promoters when exposed to a process called DNA promoter hypermethylation.

Hypermethylation is a process that causes genes that promote normal cell growth to produce proteins that cause malignant behavior, or unregulated cell growth. Until now, data has been very limited regarding the mechanism and causes of hypermethylation, especially for hypermethylation in breast cancer. The purpose of the current study was to determine how DNA hypermethylation relates to other characteristics of breast tumors.

"It is well known that mutation in genes -- alterations in their sequence -- is one of the characteristics of tumors responsible for some of their disease properties," said Menghua Tao, Ph.D., research assistant professor of social and preventive medicine in the UB School of Public Health and Health Professions and first author on the study.

"In addition, it is now becoming clear that other changes in the DNA may also contribute to the development of cancer."

The researchers analyzed methylation status in three genes, known as E-cadherin, p16 and retinoic acid B2 receptor (RAR-B2), using tissue samples from 887 breast cancers. The samples were taken from women 35-79 years old who participated in the Western New York Exposures and Breast Cancer Study (WEB study). Extensive in-person interviews were used to collect information on potential breast-cancer risk factors and confounding factors.

Results of the research were presented at the American Association of Cancer Research meeting held in Los Angeles in April.

"We found that hypermethylation of E-cadherin, but not of the other genes, was more likely to occur in estrogen receptor (ER)-negative than in ER-positive tumors," said Tao. ER-positive tumors are those that express receptors for the hormone estrogen. Such tumors respond to treatments that
'"/>

Source:University at Buffalo


Page: 1 2

Related biology news :

1. First-ever Compounds To Target Only Metastatic Cells Are Highly Effective Against Breast, Prostate, And Colon Cancers
2. Effective Cancer Treatments Follow The Clock
3. FDA Works To Speed The Advent Of New, More Effective Personalized Medicines
4. Fungus Effective Against Winged Termites
5. NCI Researchers Confirm the Effectiveness of Immunotherapy Approach to Treating Melanoma
6. Duke Experiments Boost Radiations Cancer-Killing Effects
7. Effective, safe anthrax vaccine can be grown in tobacco plants
8. Effective HIV control may depend on viral protein targeted by immune cells
9. Viral DNA sequence a possible trigger for breast cancer
10. Used in a new way, RNA interference permanently silences key breast cancer gene
11. Biomarkers isolated from saliva successfully predict oral and breast cancer
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Effect breast tumors DNA alternations genes described

(Date:2/5/2015)... TRIANGLE PARK, N.C. , Feb. 5, 2015 /PRNewswire/ ... a specialist logistics company and has launched a new ... only Clinical Logistics Organization (CLO).  The new campaign focuses ... emphasis on patient, protocol and shipments. The ... First , aligns Marken,s priorities with its client,s ...
(Date:2/5/2015)... , Jan. 27, 2015   ... of globally deployed, innovative test solutions for ... the delivery of its TS-323 GENASYS ... Systems Company (LMSSC). GENASYS is a high-performance ... of mission-critical applications that require performance functional ...
(Date:2/5/2015)... Research and Markets ( http://www.researchandmarkets.com/research/6lngtl/global_biometrics ... "Global Biometrics Market (2014-2020): Market Forecast By Technologies, ... to their offering. , In ... is anticipated to overtake North America ... spending towards IT security, government biometric based projects ...
Breaking Biology News(10 mins):Marken Launches New Patient-Centric Campaign 2Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 2Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 3Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 4Global Biometrics Market (2014-2020): Market Forecast By Technologies, Applications, End Use, Regions and Countries 2Global Biometrics Market (2014-2020): Market Forecast By Technologies, Applications, End Use, Regions and Countries 3
... people may joke about living on caffeine, but scientists ... to do that literally. Their report in the ... "addicted" to caffeine in a way that promises practical ... medications for asthma. Jeffrey E. Barrick and colleagues ...
... March 26, 2013 Like it or not and despite ... du jour for movie-making in Hollywood. It now turns out ... According to a new study published in Biological ... distinct systems: one system that directs attention to affective states ...
... treating Lyme disease. However, nearly one quarter of ... available serological tests have poor sensitivity and specificity ... may go untreated and thus progress to late-stage ... invasive treatments, as well as persistent symptoms. ...
Cached Biology News:Human emotion: We report our feelings in 3-D 2Penn Researchers attach Lyme disease antibodies to nanotubes, paving way for diagnostic device 2Penn Researchers attach Lyme disease antibodies to nanotubes, paving way for diagnostic device 3Penn Researchers attach Lyme disease antibodies to nanotubes, paving way for diagnostic device 4
(Date:3/4/2015)... BARBARA, CALIFORNIA (PRWEB) March 04, 2015 ... consulting firm in the life sciences industry, hired ... Blewitt leads the Cloud Compliance Services and Solutions ... companies utilize cloud based applications while maintaining compliance with ... years, Blewitt has been an accomplished life sciences regulatory ...
(Date:3/4/2015)... San Bruno, CA. (PRWEB) March 04, 2015 ... Organization (CRO) headquartered in the San Francisco Bay Area, ... Clinical Trials (OCT) Israel Conference 2015 on March ... PRC Clinical seeks to build relationships with Israeli life ... Administration (FDA) clinical trials. The company’s services span all ...
(Date:3/4/2015)... Korea , March 4, 2015 Vegalab ... company, in August of last year. As part of ... Kyung Bon Koo continuing his role as CEO ... President of Vegalab S.A., will work alongside Koo and ... Photo - http://photos.prnewswire.com/prnh/20150303/179218 Koo ...
(Date:3/4/2015)...   ... Therapie, Strahlendosismanagement und IT-Lösungen für die gesamte Kette ... (NYSE: PHG, AEX: PHIA) gab heute seine ... bekannt, der vom 4. bis 8. März in ... Nr. 102 and 110 wird das Unternehmen ...
Breaking Biology Technology:USDM Life Sciences Names David Blewitt VP of Cloud Compliance for Regulated Life Sciences 2USDM Life Sciences Names David Blewitt VP of Cloud Compliance for Regulated Life Sciences 3PRC Clinical to Present at Inaugural Outsourcing in Clinical Trials Israel Conference 2015 on March 25 and 26th in Tel Aviv 2PRC Clinical to Present at Inaugural Outsourcing in Clinical Trials Israel Conference 2015 on March 25 and 26th in Tel Aviv 3PRC Clinical to Present at Inaugural Outsourcing in Clinical Trials Israel Conference 2015 on March 25 and 26th in Tel Aviv 4Korean Government Program Supports Vegalab's Research and Development 2Korean Government Program Supports Vegalab's Research and Development 3Philips stellt integrierte Bildgebungslösungen auf dem Europäischen Röntgenkongress 2015 vor 2Philips stellt integrierte Bildgebungslösungen auf dem Europäischen Röntgenkongress 2015 vor 3Philips stellt integrierte Bildgebungslösungen auf dem Europäischen Röntgenkongress 2015 vor 4Philips stellt integrierte Bildgebungslösungen auf dem Europäischen Röntgenkongress 2015 vor 5Philips stellt integrierte Bildgebungslösungen auf dem Europäischen Röntgenkongress 2015 vor 6
... ... 16 Reportlinker.com announces that a new ... , The Future of Nutrigenomics: New ... , http://www.reportlinker.com/p0177850/The-Future-of-Nutrigenomics-New-opportunities-in-personalized-nutrition-and-food-pharma-collaboration.html , Nutrigenomics explores ...
... , -- Company to Host Clinical Update Conference Call ... Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ: ONCY ) today announced that ... Medicines and Healthcare products Regulatory Agency (MHRA) to conduct its ... carboplatin in patients with platinum-refractory head and neck cancers. This ...
... , , , , ROCKVILLE, Md. ... VNDA ), a biopharmaceutical company focused on the development and ... financial and operational results for the fourth quarter and full year ... net loss of $9.2 million for the fourth quarter ...
Cached Biology Technology:Reportlinker Adds The Future of Nutrigenomics: New opportunities in personalized nutrition and food-pharma collaboration 2Reportlinker Adds The Future of Nutrigenomics: New opportunities in personalized nutrition and food-pharma collaboration 3Reportlinker Adds The Future of Nutrigenomics: New opportunities in personalized nutrition and food-pharma collaboration 4Reportlinker Adds The Future of Nutrigenomics: New opportunities in personalized nutrition and food-pharma collaboration 5Reportlinker Adds The Future of Nutrigenomics: New opportunities in personalized nutrition and food-pharma collaboration 6Oncolytics Biotech(R) Inc. Receives Approval from the U.K. MHRA to Conduct Phase 3 Trial for REOLYSIN(R) in Head and Neck Cancers 2Oncolytics Biotech(R) Inc. Receives Approval from the U.K. MHRA to Conduct Phase 3 Trial for REOLYSIN(R) in Head and Neck Cancers 3Oncolytics Biotech(R) Inc. Receives Approval from the U.K. MHRA to Conduct Phase 3 Trial for REOLYSIN(R) in Head and Neck Cancers 4Oncolytics Biotech(R) Inc. Receives Approval from the U.K. MHRA to Conduct Phase 3 Trial for REOLYSIN(R) in Head and Neck Cancers 5Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2009 Results 2Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2009 Results 3Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2009 Results 4Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2009 Results 5Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2009 Results 6Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2009 Results 7Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2009 Results 8Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2009 Results 9Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2009 Results 10Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2009 Results 11Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2009 Results 12Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2009 Results 13Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2009 Results 14Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2009 Results 15Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2009 Results 16Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2009 Results 17Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2009 Results 18
... which pioneered the blending of thermostable DNA ... Expand Long Template PCR Systems, now introduces ... the first product of a family of ... combines Taq DNA Polymerase with a novel ...
... 13 5'G AATTC3' 3'CTTAA G5' Inactivation Conditions: Heat ... precipitation. Storage Conditions: 10mM Tris-HCl (pH 7.5), 100mM ... 0.01% BSA, 50% glycerol. Shipping and Storage: Shipped ... One unit is defined as the amount of ...
... 3'CGGN NNNNCCG5' Inactivation Conditions: Heat inactivation at ... followed by ethanol precipitation. Storage Conditions: 10mM ... 1.0mM DTT, 0.01% BSA, 50% glycerol. Shipping ... at -20C. Unit Definition: One unit is ...
...
Biology Products: